Algeria Bets on African Health Sovereignty as It Pushes for a Continental Pharmaceutical Manufacturing Hub
Building on high-level talks in Algiers between Africa CDC Director-General Jean Kaseya and senior Algerian officials, Algeria is positioning itself at the heart of Africa’s drive for pharmaceutical self-sufficiency—leveraging local manufacturing, technology transfer, regional procurement and scientific cooperation to reduce the continent’s dependence on imported medicines and strengthen long-term health security.
By Dr. Hana Saada
ALGIERS — Algeria is intensifying its bid to become a strategic pillar of Africa’s pharmaceutical transformation, as a series of high-level meetings with Africa Centres for Disease Control and Prevention (Africa CDC) Director-General Dr. Jean Kaseya underscored a shared commitment to expanding local drug and vaccine production, strengthening regional health institutions and advancing the continent’s ambition for greater medical self-reliance.
The discussions, held separately with Minister of Pharmaceutical Industry Ouacim Kouidri and Minister of Health Mohamed Seddik Ait Messaoudene, reflect a broader shift in Algeria’s healthcare strategy—from expanding domestic production capacity to positioning itself as a regional manufacturing, research and training hub capable of supporting African health systems beyond its borders.
Rather than viewing pharmaceutical manufacturing solely through an industrial lens, Algerian policymakers increasingly frame the sector as a cornerstone of national and continental security, arguing that resilient health systems depend on reliable local production, scientific innovation and integrated regional supply chains.
Central to those discussions was the implementation of the Algiers Declaration, adopted during the African Ministerial Conference on Local Pharmaceutical Production and Health Technologies in November 2025. The roadmap advocates the creation of regional manufacturing clusters, accelerated technology transfer, stronger regulatory cooperation and expanded African pharmaceutical production as part of a long-term strategy to build sustainable health sovereignty across the continent.
The meetings also highlighted the growing importance of pooled procurement mechanisms for medicines and vaccines, an approach increasingly promoted by Africa CDC as a means of strengthening African countries’ collective purchasing power, improving supply-chain resilience and expanding equitable access to essential medical products during both routine healthcare delivery and future health emergencies.
Kaseya also met Health Minister Mohamed Seddik Ait Messaoudene to discuss broader cooperation on epidemic preparedness, emergency response, workforce development, digital health and scientific collaboration. The exchanges reinforced Algeria’s expanding role within Africa CDC’s institutional architecture, particularly following the designation of the Pasteur Institute of Algeria as North Africa’s regional centre of excellence for biosafety and biosecurity.
Algerian authorities are simultaneously advancing domestic initiatives intended to reinforce that regional role, including plans to expand local vaccine manufacturing, establish a specialised regional vaccinology platform and develop a health cooperation centre in Tamanrasset designed to serve neighbouring African countries through training, immunisation programmes and technical assistance.
The strategy extends beyond manufacturing capacity alone. Officials increasingly link pharmaceutical sovereignty with digital transformation, regulatory modernisation and scientific research, while expanding telemedicine, digital health records and integrated pharmaceutical management systems as part of wider efforts to modernise healthcare governance.
According to Dr. Chérif Imane, an epidemiology specialist interviewed by Elayem.news, Africa’s experience during the COVID-19 pandemic fundamentally reshaped thinking about health security by exposing the strategic vulnerabilities created by excessive dependence on imported medicines and vaccines.
She argues that sustainable pharmaceutical independence requires more than constructing factories. Lasting resilience, she says, depends on integrating industrial production with scientific research, technology transfer, workforce development and innovation ecosystems capable of producing internationally competitive medicines and vaccines.
In her assessment, Algeria’s expanding pharmaceutical base, combined with its research institutions and growing manufacturing expertise, places the country in a favourable position to contribute to a more integrated African health architecture. The partnership with Africa CDC, she contends, gives those national capabilities a continental dimension by facilitating knowledge exchange, regulatory cooperation and joint industrial development.
She also identifies technology transfer as the decisive factor separating simple production expansion from genuine pharmaceutical autonomy. Manufacturing facilities, she notes, cannot achieve strategic value without access to advanced production technologies, specialised scientific expertise and sustained investment in research and development.
Equally significant, she says, are regional procurement mechanisms, which could allow African governments to negotiate collectively, secure more competitive prices, stabilise supply chains and improve access to essential medicines during periods of heightened global demand.
Taken together, local manufacturing, technology transfer and coordinated procurement could gradually lay the foundations for a more integrated African pharmaceutical market—one that distributes production across the continent according to industrial capabilities while reducing structural dependence on external suppliers.
For Algeria, that vision aligns with a broader economic and geopolitical strategy that places scientific capacity alongside industrial diversification as instruments of regional influence. As African governments increasingly seek to build resilient health systems through continental cooperation rather than external dependence, Algiers appears determined to position itself not merely as a pharmaceutical producer, but as one of the architects of Africa’s emerging health sovereignty.
Adapted from:
— 𝐄𝐍𝐃 —
Dzair Tube Media Group | Record and Standing
Dzair Tube is a leading Algerian digital journalism platform, delivering high-quality content in Arabic, French, and English. With a daily readership exceeding 500,000, it has established itself among the country’s most influential media organizations.
Recognized for editorial excellence and integrity, Dzair Tube was awarded the President of the Republic’s Prize for Professional Journalist in the Electronic Press category on 22 October 2022. The platform operates from state-of-the-art studios, producing diverse programming across news, sports, culture, entertainment, and religion.
Dzair Tube maintains a robust digital presence, with over 600,000 YouTube subscribers, six million followers across Facebook pages, and more than 70,000 Instagram followers. Its sports daily, Dzair Sport, enjoys over 50,000 daily downloads via its official website, cementing its leadership in multimedia journalism.
Further recognized with the Media Leadership Award by former Minister of Communication Mohamed Laâgab and celebrated at the Hilals of Television awards, Dzair Tube continues to set benchmarks in innovation, influence, and public engagement, serving as a key forum for civic discourse, critical analysis, and public affairs.
Official website: www.dzair-tube.dz | English: www.dzair-tube.dz/en
